Search

Your search keyword '"Kasuga, Kensaku"' showing total 354 results

Search Constraints

Start Over You searched for: Author "Kasuga, Kensaku" Remove constraint Author: "Kasuga, Kensaku" Publication Year Range Last 50 years Remove constraint Publication Year Range: Last 50 years
354 results on '"Kasuga, Kensaku"'

Search Results

1. CSF proteomics identifies early changes in autosomal dominant Alzheimer’s disease

2. γ-Secretase activity, clinical features, and biomarkers of autosomal dominant Alzheimer's disease: cross-sectional and longitudinal analysis of the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS)

4. Sex difference in evolution of cognitive decline: studies on mouse model and the Dominantly Inherited Alzheimer Network cohort

5. Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study

6. Deconstructing pathological tau by biological process in early stages of Alzheimer disease: a method for quantifying tau spatial spread in neuroimaging

7. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis

11. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study

12. Brain p3‐Alcβ peptide restores neuronal viability impaired by Alzheimer's amyloid β‐peptide

14. Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease

15. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study

16. Public perceptions related to healthcare preparedness to anti-amyloid therapies for Alzheimer's Disease in Japan.

17. Alzheimer's Disease-Related Cerebrospinal Fluid Biomarkers in Progressive Supranuclear Palsy.

19. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly

20. Deconstructing pathological tau by biological process in early stages of Alzheimer disease: a method for quantifying tau spatial spread in neuroimaging

23. Demographic, clinical, biomarker, and neuropathological correlates of posterior cortical atrophy: an international cohort study and individual participant data meta-analysis

28. Decrease in p3-Alcβ37 and p3-Alcβ40, products of Alcadein β generated by γ-secretase cleavages, in aged monkeys and patients with Alzheimer's disease

29. Polygenic effects on the risk of Alzheimer′s disease in the Japanese population

30. Heterogenous Genetic, Clinical, and Imaging Features in Patients with Neuronal Intranuclear Inclusion Disease Carrying NOTCH2NLC Repeat Expansion

31. Polygenic effects on the risk of Alzheimer's disease in the Japanese population.

33. Identification and functional characterization of novel mutations including frameshift mutation in exon 4 of CSF1R in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia

34. Novel Partial Deletions, Frameshift and Missense Mutations ofCSF1Rin Patents withCSF1R ‐RelatedLeukoencephalopathy

36. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal observational study

37. Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study

38. Decreased circulating branched-chain amino acids are associated with development of Alzheimer’s disease in elderly individuals with mild cognitive impairment

39. Estimation of blood-based biomarkers of glial activation related to neuroinflammation

40. Biomarkers and neuropathology in posterior cortical atrophy: an international, multi‐site study

41. Change in cerebrospinal fluid tau microtubule binding region detects symptom onset, cognitive decline, tangles, and atrophy in Dominantly Inherited Alzheimer's Disease

43. Involvement of inflammation in the medial temporal region in the development of agitation in Alzheimer's disease: an in vivo positron emission tomography study

44. The Clinical Application of Optimized AT(N) Classification in Alzheimer’s Clinical Syndrome (ACS) and non-ACS Conditions

45. Generation of a gene-corrected human isogenic iPSC line from an Alzheimer’s disease iPSC line carrying the PSEN1 H163R mutation

46. Different AT(N) profiles and clinical progression classified by two different N markers using total tau and neurofilament light chain in cerebrospinal fluid

47. Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease

48. The role of dyadic cognitive report and subjective cognitive decline in early ADRD clinical research and trials: current knowledge, gaps, and recommendations

50. Predicting brain age from functional connectivity in symptomatic and preclinical Alzheimer disease

Catalog

Books, media, physical & digital resources